Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Capital Expenditures (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Capital Expenditures for 6 consecutive years, with $14.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 695.86% to $14.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $19.0 million, a N/A change, with the full-year FY2025 number at $19.0 million, changed N/A from a year prior.
  • Capital Expenditures was $14.5 million for Q4 2025 at GeneDx Holdings, up from -$4.0 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $14.5 million in Q4 2025 to a low of -$4.0 million in Q3 2025.
  • A 5-year average of $1.6 million and a median of $1.4 million in 2022 define the central range for Capital Expenditures.
  • Biggest YoY gain for Capital Expenditures was 10763.79% in 2025; the steepest drop was 307.53% in 2025.
  • GeneDx Holdings' Capital Expenditures stood at -$3.6 million in 2021, then skyrocketed by 118.76% to $672000.0 in 2022, then crashed by 31.4% to $461000.0 in 2023, then crashed by 629.5% to -$2.4 million in 2024, then skyrocketed by 695.86% to $14.5 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's Capital Expenditures are $14.5 million (Q4 2025), -$4.0 million (Q3 2025), and $6.3 million (Q2 2025).